Trials / Completed
CompletedNCT03329846
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986205 | specified dose on specified day |
| BIOLOGICAL | Nivolumab | Specified dose on specified day |
| DRUG | Placebo | Specified dose on specified day |
Timeline
- Start date
- 2017-11-30
- Primary completion
- 2020-07-02
- Completion
- 2020-07-02
- First posted
- 2017-11-06
- Last updated
- 2021-07-09
- Results posted
- 2021-07-09
Locations
63 sites across 16 countries: United States, Australia, Canada, Czechia, France, Germany, Greece, Ireland, Italy, Japan, Netherlands, New Zealand, Poland, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03329846. Inclusion in this directory is not an endorsement.